Tatiana Froud
Overview
Explore the profile of Tatiana Froud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Narayanan G, Hosein P, Beulaygue I, Froud T, Scheffer H, Venkat S, et al.
J Vasc Interv Radiol
. 2016 Dec;
28(3):342-348.
PMID: 27993507
Purpose: To describe safety and effectiveness of percutaneous irreversible electroporation (IRE) for treatment of unresectable, locally advanced pancreatic adenocarcinoma (LAPC). Materials And Methods: This retrospective study included 50 patients (23...
2.
Froud T, Venkat S, Barbery K, Gunjan A, Narayanan G
Tech Vasc Interv Radiol
. 2015 Sep;
18(3):140-6.
PMID: 26365543
Irreversible electroporation (IRE) is a relatively new ablation modality that uses electric currents to cause cell death. It is commonly used to treat primary and secondary liver tumors in patients...
3.
Bhatia S, Spector S, Echenique A, Froud T, Suthar R, Lawson I, et al.
Cardiovasc Intervent Radiol
. 2014 Nov;
38(4):922-8.
PMID: 25392237
Purpose: The purpose of this study was to evaluate need for antibiotic prophylaxis for radiofrequency ablation (RFA) of liver tumors in patients with no significant co-existing risk factors for infection....
4.
Hosein P, Echenique A, Loaiza-Bonilla A, Froud T, Barbery K, Rocha Lima C, et al.
J Vasc Interv Radiol
. 2014 May;
25(8):1233-1239.e2.
PMID: 24861662
Purpose: To describe an initial experience with irreversible electroporation (IRE) in patients with colorectal liver metastasis (CLM). Materials And Methods: A retrospective analysis of patients undergoing IRE for the management...
5.
Narayanan G, Froud T, Suthar R, Barbery K
Semin Intervent Radiol
. 2014 Jan;
30(1):67-73.
PMID: 24436519
Hepatocellular carcinoma (HCC) is a worldwide problem of epidemic proportions, best treated in a multidisciplinary setting. Major advances have been made in all specialties that manage patients with HCC, with...
6.
Colak Bozkurt N, Peixoto E, Froud T, Herrada E, Corrales A, Ricordi C, et al.
Transplantation
. 2013 Jun;
95(12):e73-6.
PMID: 23774776
No abstract available.
7.
Narayanan G, Hosein P, Arora G, Barbery K, Froud T, Livingstone A, et al.
J Vasc Interv Radiol
. 2012 Nov;
23(12):1613-21.
PMID: 23177107
Purpose: Treatment of unresectable locally advanced pancreatic cancer (LAPC) usually includes chemotherapy and/or radiation therapy in an attempt to downstage these tumors to the extent of resectability, but outcomes remain...
8.
Narayanan G, Froud T, Lo K, Barbery K, Perez-Rojas E, Yrizarry J
Cardiovasc Intervent Radiol
. 2012 Jul;
36(1):176-82.
PMID: 22752100
Purpose: To retrospectively compare the postprocedure pain of hepatocellular carcinoma treated with irreversible electroporation (IRE) with radiofrequency ablation (RFA). Methods: This Health Insurance Portability and Accountability Act-compliant, institutional review board-approved...
9.
Froud T, Ricordi C, Alejandro R
Transplantation
. 2010 Aug;
87(1):154.
PMID: 20737025
No abstract available.
10.
Faradji R, Froud T, Messinger S, Monroy K, Pileggi A, Mineo D, et al.
Cell Transplant
. 2009 Dec;
18(10):1247-59.
PMID: 20003758
The initial success of islet transplantation (ITx) is followed by graft dysfunction (GDF) and insulin reintroduction. Exenatide, a GLP-1 agonist, increases insulin and decreases glucagon secretion and has potential for...